Page last updated: 2024-11-13
sansalvamide a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
sansalvamide A: a cyclic depsipeptide; inhibits poxvirus topoisomerase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 44426202 |
CHEMBL ID | 228860 |
MeSH ID | M0305655 |
Synonyms (2)
Synonym |
---|
CHEMBL228860 |
sansalvamide a |
Research Excerpts
Overview
Sansalvamide A is a cyclic depsipeptide produced by a marine fungus.
Excerpt | Reference | Relevance |
---|---|---|
"Sansalvamide A is a cyclic depsipeptide produced by a marine fungus." | ( A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Adrian, TE; Bell, RH; Ding, XZ; Gu, W; Milam, B; Roginsky, AB; Salabat, MR; Silverman, RB; Talamonti, MS; Ujiki, MB, 2006) | 1.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID292673 | Cytotoxicity against BxPC3 cells at 5 uM by [3H]thymidine inhibition assay | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. |
AID292672 | Cytotoxicity against PL45 cells at 5 uM by [3H]thymidine inhibition assay | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. |
AID292674 | Cytotoxicity against WS1 cells | 2007 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18 | Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (26)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.85) | 18.2507 |
2000's | 14 (53.85) | 29.6817 |
2010's | 11 (42.31) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.93) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 26 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |